Recommended Topic Related To:

Eylea

"Nov. 12, 2012 -- iPads and other tablets with backlit screens may allow millions of people with "low vision" to read faster and easier, a new study suggests.

Low vision is an umbrella term for people who still have trouble reading, wa"...

Eylea

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in the WARNINGS AND PRECAUTIONS section of the labeling:

The most common adverse reactions ( ≥ 5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.

Injection Procedure

Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections with EYLEA including endophthalmitis, traumatic cataract, increased intraocular pressure, and vitreous detachment.

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice.

A total of 2042 patients treated with EYLEA constituted the safety population in four phase 3 studies. Among those, 1441 patients were treated with the recommended dose of 2 mg.

Neovascular (Wet) Age-Related Macular Degeneration (AMD)

The data described below reflect exposure to EYLEA in 1824 patients with wet AMD, including 1223 patients treated with the 2-mg dose, in 2 double-masked, active-controlled clinical studies (VIEW1 and VIEW2) for 12 months [see Clinical Studies].

Table 1: Most Common Adverse Reactions ( ≥ 1%) in Wet AMD Studies

Adverse Reactions EYLEA
(N=1824)
Active Control (ranibizumab)
(N=595)
Conjunctival hemorrhage 25% 28%
Eye pain 9% 9%
Cataract 7% 7%
Vitreous detachment 6% 6%
Vitreous floaters 6% 7%
Intraocular pressure increased 5% 7%
Conjunctival hyperemia 4% 8%
Corneal erosion 4% 5%
Detachment of the retinal pigment epithelium 3% 3%
Injection site pain 3% 3%
Foreign body sensation in eyes 3% 4%
Lacrimation increased 3% 1%
Vision blurred 2% 2%
Intraocular inflammation 2% 3%
Retinal pigment epithelium tear 2% 1%
Injection site hemorrhage 1% 2%
Eyelid edema 1% 2%
Corneal edema 1% 1%

Less common serious adverse reactions reported in < 1% of the patients treated with EYLEA were hypersensitivity, retinal detachment, retinal tear, and endophthalmitis.

Macular Edema Following Central Retinal Vein Occlusion (CRVO)

The data described below reflect exposure to EYLEA in 218 patients with macular edema following CRVO treated with 2 mg dose in 2 double-masked, controlled clinical studies (GALILEO and COPERNICUS) for 6 months [see Clinical Studies].

Table 2: Most Common Adverse Reactions ( ≥ 1%) in CRVO Studies

Adverse Reactions EYLEA
(N=218)
Control
(N=142)
Eye pain 13% 5%
Conjunctival hemorrhage 12% 11%
Intraocular pressure increased 8% 6%
Corneal erosion 5% 4%
Vitreous floaters 5% 1%
Conjunctival hyperemia 5% 3%
Foreign body sensation in eyes 3% 5%
Vitreous detachment 3% 4%
Lacrimation increased 3% 4%
Injection site pain 3% 1%
Vision blurred 1% < 1%
Intraocular inflammation 1% 1%

Less common adverse reactions reported in < 1% of the patients treated with EYLEA were cataract, eyelid edema, corneal edema, retinal tear, hypersensitivity and endophthalmitis.

Immunogenicity

As with all therapeutic proteins, there is a potential for an immune response in patients treated with EYLEA. The immunogenicity of EYLEA was evaluated in serum samples. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to EYLEA in immunoassays. The detection of an immune response is highly dependent on the sensitivity and specificity of the assays used, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to EYLEA with the incidence of antibodies to other products may be misleading.

In the wet AMD and CRVO studies, the pre-treatment incidence of immunoreactivity to EYLEA was 1% to 3% across treatment groups. After dosing with EYLEA for 52 weeks (wet AMD), or 24 weeks (CRVO), antibodies to EYLEA were detected in a similar percentage range of patients. Both in the wet AMD and in the CRVO studies, there were no differences in efficacy or safety between patients with or without immunoreactivity.

Read the Eylea (aflibercept) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

No information provided.

Last reviewed on RxList: 2/7/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.